CB2 Receptor
Cannabinoid receptor type 2. A GPCR primarily expressed in immune tissues and peripheral organs. Less abundant in the CNS than CB1.
In Depth
CB2 receptors are predominantly found on immune cells (B cells, NK cells, monocytes, macrophages) and in peripheral tissues including the spleen, tonsils, and bone marrow. They are also expressed in the liver, gut, and bone. CB2 activation generally produces anti-inflammatory effects without psychoactivity, making CB2-selective agonists attractive therapeutic targets for inflammatory and autoimmune conditions. CB2 expression in the brain increases under neuroinflammatory conditions.
Related Terms
Further Reading
More in Pharmacology
Endocannabinoid System (ECS)
A lipid-based retrograde neurotransmitter system comprising endogenous cannabinoids (endocannabinoids), their receptors (CB1, CB2), and metabolic enzymes.
CB1 Receptor
Cannabinoid receptor type 1. A G protein-coupled receptor (GPCR) primarily expressed in the central nervous system. The primary target of THC's psychoactive effects.
Anandamide (AEA)
N-arachidonoylethanolamine. The first endocannabinoid identified. A partial agonist at CB1 and CB2 receptors, named from the Sanskrit word "ananda" meaning bliss.
2-Arachidonoylglycerol (2-AG)
The most abundant endocannabinoid in the brain. A full agonist at both CB1 and CB2 receptors.
FAAH (Fatty Acid Amide Hydrolase)
The primary enzyme responsible for degrading anandamide and other fatty acid amides. A key target for increasing endocannabinoid tone.